Fixed-dose combination bictegravir–emtricitabine–tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial

Clinical Trial
HIV
TB
Phase 2b
Trial Outcomes
Y2026
The Lancet HIV
Published

January 1, 2026

Keywords

Collaborations, Analysis, Biostatistics, Data Curation, Clinical Trial, HIV, TB, Phase 2b, Trial Outcomes, Y2026

Year: 2026 Journal: The Lancet HIV DOI: 10.1016/s2352-3018(25)00200-0 Source: http://dx.doi.org/10.1016/s2352-3018(25)00200-0